Drugs / CART-EGFR-IL13Ra2 T cells
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07209241 Comparator | Dec 2025 → Nov 2042 expected | glioblastoma | University of Pennsylvania | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART-EGFR-IL13Ra2 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07209241 ↗ |
| Modality | Cell therapy | “autologous T cells” NCT07209241 ↗ |
| Target | EGFR | “CART-EGFR-IL13Ra2 cells are autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806” NCT07209241 ↗ |
| Target | IL13RA2 | “CART-EGFR-IL13Ra2 cells are autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806” NCT07209241 ↗ |